Cellectis S.A. (CMVLF)
USD 1.25
(0.0%)
USD 1.25
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 97.32 Million USD | -15.94% |
| 2022 | 107.06 Million USD | -13.03% |
| 2021 | 123.11 Million USD | 0.0% |
| 2020 | 123.11 Million USD | -3.33% |
| 2019 | 127.35 Million USD | 10.66% |
| 2018 | 115.08 Million USD | -0.12% |
| 2017 | 115.21 Million USD | 9.88% |
| 2016 | 104.85 Million USD | 26.54% |
| 2015 | 82.86 Million USD | 185.89% |
| 2014 | 28.98 Million USD | -56.82% |
| 2013 | 67.12 Million USD | 29.28% |
| 2012 | 51.92 Million USD | 21.38% |
| 2011 | 42.77 Million USD | 24.69% |
| 2010 | 34.3 Million USD | 24.7% |
| 2009 | 27.51 Million USD | 52.61% |
| 2008 | 18.02 Million USD | 73.23% |
| 2007 | 10.4 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 22.72 Million USD | -13.8% |
| 2024 Q2 | 27.18 Million USD | 19.62% |
| 2023 Q1 | 23.23 Million USD | 10.68% |
| 2023 Q3 | 20.64 Million USD | -13.19% |
| 2023 Q4 | 26.36 Million USD | 27.7% |
| 2023 Q2 | 23.78 Million USD | 2.35% |
| 2023 FY | 90 Million USD | -15.94% |
| 2022 Q4 | 20.99 Million USD | -36.4% |
| 2022 Q1 | 36.56 Million USD | 7.0% |
| 2022 Q2 | 35.09 Million USD | -4.0% |
| 2022 Q3 | 33.01 Million USD | -5.94% |
| 2022 FY | 107.06 Million USD | -13.03% |
| 2021 Q4 | 34.16 Million USD | -17.6% |
| 2021 Q1 | 37.36 Million USD | 9.34% |
| 2021 FY | 123.11 Million USD | 0.0% |
| 2021 Q2 | 36.9 Million USD | -1.23% |
| 2021 Q3 | 41.46 Million USD | 12.37% |
| 2020 Q1 | 31.11 Million USD | -16.5% |
| 2020 FY | 123.11 Million USD | -3.33% |
| 2020 Q2 | 30.1 Million USD | -3.25% |
| 2020 Q3 | 27.71 Million USD | -7.94% |
| 2020 Q4 | 34.16 Million USD | 23.28% |
| 2019 Q4 | 37.26 Million USD | 20.67% |
| 2019 Q3 | 30.88 Million USD | -12.92% |
| 2019 FY | 127.35 Million USD | 10.66% |
| 2019 Q2 | 35.46 Million USD | 50.47% |
| 2019 Q1 | 23.56 Million USD | -20.15% |
| 2018 Q4 | 29.51 Million USD | 1.98% |
| 2018 FY | 115.08 Million USD | -0.12% |
| 2018 Q3 | 28.93 Million USD | 10.52% |
| 2018 Q2 | 26.18 Million USD | -13.76% |
| 2018 Q1 | 30.36 Million USD | -6.88% |
| 2017 FY | 115.21 Million USD | 9.88% |
| 2017 Q1 | 25.96 Million USD | -4.54% |
| 2017 Q2 | 26.8 Million USD | 3.22% |
| 2017 Q3 | 31.25 Million USD | 16.62% |
| 2017 Q4 | 32.6 Million USD | 4.32% |
| 2016 Q4 | 27.2 Million USD | 13.65% |
| 2016 FY | 104.85 Million USD | 26.54% |
| 2016 Q2 | 28.42 Million USD | -6.96% |
| 2016 Q1 | 30.54 Million USD | 14.22% |
| 2016 Q3 | 23.93 Million USD | -15.79% |
| 2015 Q1 | 12.51 Million USD | 162.87% |
| 2015 Q4 | 26.74 Million USD | 14.76% |
| 2015 FY | 82.86 Million USD | 185.89% |
| 2015 Q3 | 23.3 Million USD | 9.0% |
| 2015 Q2 | 21.38 Million USD | 70.81% |
| 2014 FY | 28.98 Million USD | -56.82% |
| 2014 Q4 | 4.76 Million USD | -4.09% |
| 2014 Q3 | 4.96 Million USD | -47.65% |
| 2014 Q2 | 9.48 Million USD | -0.64% |
| 2014 Q1 | 9.54 Million USD | -27.3% |
| 2013 Q2 | 12.98 Million USD | 1.46% |
| 2013 FY | 67.12 Million USD | 29.28% |
| 2013 Q1 | 12.79 Million USD | 0.0% |
| 2013 Q3 | 12.9 Million USD | -0.61% |
| 2013 Q4 | 13.12 Million USD | 1.75% |
| 2012 FY | 51.92 Million USD | 21.38% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | 42.77 Million USD | 24.69% |
| 2010 FY | 34.3 Million USD | 24.7% |
| 2009 FY | 27.51 Million USD | 52.61% |
| 2008 FY | 18.02 Million USD | 73.23% |
| 2007 FY | 10.4 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -7187.535% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -1830.17% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -229.307% |
| Nascent Biotech, Inc. | 2.22 Million USD | -4264.362% |
| Rebus Holdings, Inc. | 664 Thousand USD | -14556.627% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -161.222% |
| Qrons Inc. | 643.67 Thousand USD | -15019.384% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -24881.646% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -69.429% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -23323.567% |
| Skye Bioscience, Inc. | 13.54 Million USD | -618.359% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -12.139% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -1878.888% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -37083.925% |
| SQZ Biotechnologies Company | 85.61 Million USD | -13.666% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -3237.18% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -6379.797% |
| Mesoblast Limited | 5.9 Million USD | -1548.933% |
| Marizyme, Inc. | 19.23 Million USD | -405.826% |
| Genus plc | 147.7 Million USD | 34.11% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1008.525% |
| Pharming Group N.V. | 225.49 Million USD | 56.841% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -4650.318% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -7154.322% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1067.046% |
| ContraFect Corporation | 56.88 Million USD | -71.07% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -2107.467% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -6481.225% |
| IMV Inc. | 37.7 Million USD | -158.08% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -3387.726% |
| MultiCell Technologies, Inc. | 567.42 USD | -17151216.485% |
| ONE Bio Corp. | 6.44 Million USD | -1410.267% |
| Accustem Sciences Inc. | 3.74 Million USD | -2497.681% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -13.235% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -18194.54% |
| Q BioMed Inc. | 3.43 Million USD | -2731.846% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -293.769% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -3603.87% |
| Biomind Labs Inc. | 994.18 Thousand USD | -9688.952% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 2.024% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -5430.557% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -1348.642% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -5119.994% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 389380.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -507.861% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -5203.268% |
| GB Sciences, Inc. | 1.42 Million USD | -6751.065% |
| Alpha Cognition Inc. | 9.7 Million USD | -902.72% |
| HST Global, Inc. | 140.9 Thousand USD | -68966.831% |
| CSL Limited | 3.44 Billion USD | 97.178% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -8551.359% |
| Halberd Corporation | 74.84 Thousand USD | -129933.938% |
| Enzolytics Inc. | 2.17 Million USD | -4365.23% |
| Agentix Corp. | 1.37 Million USD | -6994.556% |
| Resverlogix Corp. | 12.71 Million USD | -665.576% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -2565.785% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 93.654% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -9221.839% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -3946.681% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -6062.009% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -2758.167% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1231.279% |
| Zenith Capital Corp. | 8.94 Million USD | -988.225% |
| Genscript Biotech Corporation | 825.34 Million USD | 88.209% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -558536.129% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -3863.643% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -56643.378% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -4966.359% |
| Kadimastem Ltd | 2.41 Million USD | -3937.987% |
| Helix BioMedix, Inc. | 1.97 Million USD | -4835.006% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -795.555% |
| BioStem Technologies, Inc. | 22.97 Million USD | -323.595% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -53524.266% |
| LadRx Corporation | 3.81 Million USD | -2453.131% |
| Cell Source, Inc. | 4.32 Million USD | -2149.993% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -10438.056% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -10438.056% |
| NovAccess Global Inc. | 2.46 Million USD | -3845.255% |
| Affymax, Inc. | 39.38 Million USD | -147.093% |
| Itoco Inc. | 919.14 Thousand USD | -10488.124% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -2196.142% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -8597.051% |
| Mobile Lads Corp. | 554.54 Thousand USD | -17449.491% |
| CytoDyn Inc. | 18.05 Million USD | -438.93% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -386566.137% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -44120.685% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -6754.525% |
| SYBLEU INC | 160.87 Thousand USD | -60393.796% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -5258.087% |
| International Stem Cell Corporation | 5.27 Million USD | -1746.329% |
| Bioxytran, Inc. | 3.82 Million USD | -2447.546% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -184771.395% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -478295.517% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -168.351% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -5914.833% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -13125.791% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -3028.255% |
| Neutra Corp. | 243.82 Thousand USD | -39814.527% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -457.484% |
| PureTech Health plc | 144.59 Million USD | 32.696% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -374.966% |
| IXICO plc | 4.7 Million USD | -1967.559% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1006.286% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 17.349% |
| CSL Limited | 3.89 Billion USD | 97.5% |